Apoquel Chewable is an FDA-approved chewable treatment in the U.S. prescribed to control itching associated with allergic ...

ZTS delivered second-quarter 2025 adjusted earnings (excluding one-time items) of $1.76 per share, which surpassed the Zacks ...

In terms of drug class, immunosuppressants hold the largest market share, accounting for 42.10% in 2024. Their effectiveness ...

Applying a daily emollient on infants younger than aged 9 weeks reduced the risk for atopic dermatitis by 16% at 24 months ...

Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the ...

A new study published in the Journal of American Medical Association showed that daily application of full-body emollients during the first 9 weeks of life significantly reduced the risk ...

Oregon Health & Science University-led research is reporting that daily full-body emollient use starting before 9 weeks of ...

In a population not selected for risk, the cumulative incidence of atopic dermatitis at 24 months was 36.1% for those in the daily emollients group versus 43% for those in the control group (relative ...

Investing.com -- Elanco Animal Health (NYSE: ELAN) stock rose 2.6% following the European Commission’s approval of Zenrelia, a once-daily oral treatment for canine allergic dermatitis.

The JAK-inhibitor will be available to veterinarians and itchy dog owners in the United Kingdom by the end of Q3 2025.

Scratching, licking, and rolling around on their tummy are common behaviors in dogs, but sometimes these actions can get out ...

Elanco Animal Health said it has received marketing authorization for Zenrelia, a dermatology treatment for dogs, from the European Commission. The animal health products and services provider said ...